00:47 , Jun 18, 2019 |  BC Extra  |  Company News

Latest twist in uniQure’s tale: possible sale

Five years after returning to the public markets, uniQure may be on the block. While the Dutch gene therapy play declined to comment on a Bloomberg report citing undisclosed sources that the biotech was exploring...
00:06 , Apr 6, 2019 |  BioCentury  |  Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
01:10 , Mar 2, 2019 |  BioCentury  |  Product Development

Roche broadens its BD scope

Roche’s proposed acquisition of Spark Therapeutics Inc. is the pharma’s first major deal since James Sabry took over partnering, and could be a glimpse of what’s to come as the pharma broadens its horizons on...
23:27 , Feb 13, 2019 |  BC Week In Review  |  Clinical News

uniQure gene therapy leads to sustained Factor IX activity in Phase IIb study

uniQure N.V. (NASDAQ:QURE) said Feb. 8 new data showed sustained Factor IX activity in a Phase IIb study of gene therapy AMT-061 to treat hemophilia B. Separately, the company said Feb. 4 it had dosed...
18:36 , Feb 8, 2019 |  BC Extra  |  Clinical News

uniQure gets bump on latest hemophilia readout

uniQure N.V. (NASDAQ:QURE) added $3.31 (10%) to $36.49 Friday after new data showed sustained Factor IX activity in a Phase IIb study of gene therapy AMT-061 to treat hemophilia B. Separately, the company said Monday...
03:50 , Dec 1, 2018 |  BioCentury  |  Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
18:04 , Nov 16, 2018 |  BC Week In Review  |  Clinical News

uniQure hemophilia B gene therapy leads to Factor IX activity level of 31% of normal

uniQure N.V. (NASDAQ:QURE) reported that all three patients who received hemophilia B gene therapy AMT-061 in a dose-confirmation Phase IIb trial achieved and sustained therapeutic levels of Factor IX activity. The company has started enrollment...
21:57 , Nov 15, 2018 |  BC Extra  |  Clinical News

uniQure gains on Factor IX activity data for hemophilia B gene therapy

uniQure N.V. (NASDAQ:QURE) added $8.13 (36%) to $30.93 on Thursday after reporting that all three patients who received hemophilia B gene therapy AMT-061 in a dose-confirmation Phase IIb trial achieved and sustained therapeutic levels of...
23:07 , Jul 20, 2018 |  BioCentury  |  Regulation

FDA’s positive reinforcement

Companies are still sifting through a half dozen gene therapy guidance documents issued by FDA, but so far it appears the recommendations support the paths taken by some of the most advanced clinical candidates for...
13:01 , May 25, 2018 |  BioCentury  |  Product Development

Patients at the core

With excitement mounting for the seven hemophilia gene therapies in the clinic, the National Hemophilia Foundation wanted to avoid a scenario in which patients, physicians and payers had no good way to compare them. The...